Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo
Betsy Goodfellow | August 23, 2023 | News story | Research and Development |Â Â Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancerÂ
Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).
The trial compared Retevmo with multikinase inhibitors (MKIs) cabozantinib or vendetanib for this indication, and met its primary endpoint, meaning it demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS).
LIBRETTO-531 was the first randomised trial to compare the safety and effectiveness of a highly selective RET-kinase inhibitor versus MKIs for this indication.
David Hyman, MD, chief medical officer of Loxo@Lilly, commented: “These data from the LIBRETTO-531 trial confirm the importance of selectivity in targeting RET-driven cancers and suggest Retevmo should be considered the preferred first-line treatment for people with advanced RET-mutant medullary thyroid cancer. Taken together with the recent positive Retevmo Phase 3 LIBRETTO-431 announcement in lung cancer, these results underscore the importance of timely and broad-based genomic testing to ensure patients who could potentially benefit receive targeted therapies. We look forward to sharing detailed data with the oncology community.”
Full results of this trial are expected to be presented at an upcoming medical meeting, submitted to a peer-reviewed journal and ultimately discussed with the relevant health authorities.
Betsy Goodfellow
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
